Home › Funds › Opaleye Management Inc. › NTLA
Opaleye Management Inc. position in NTLA
INTELLIA THERAPEUTICS INC · Health Care
Opaleye Management Inc. reported holding 250,000 shares of NTLA (INTELLIA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$4.2M, representing 0.38% of its reported portfolio and ranking #38 among its reported holdings. Opaleye Management Inc. has disclosed NTLA holdings in 5 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s NTLA position evolved
Opaleye Management Inc. first disclosed a stake in NTLA in Q4 2023 at 99,000 shares (US$3.0M). The position peaked in Q1 2024 at 255,000 shares, worth US$7.0M. Across 5 filings, Opaleye Management Inc. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 250,000 shares valued at US$4.2M — an increase of 5,000 shares quarter over quarter.. Notable position changes include a 158% increase in Q1 2024 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 99.00K | $3.02M | New |
| Q1 2024 | 255.00K | $7.02M | Add |
| Q2 2024 | 218.00K | $4.88M | Reduce |
| Q1 2026 | 245.00K | $3.14M | New |
| Q2 2026 | 250.00K | $4.23M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NTLA and 13F data
NTLA (INTELLIA THERAPEUTICS INC) is a Health Care company. 39 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$285.5M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), REGENERON PHARMACEUTICALS, INC. (US$62.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NTLA
- ARK Invest 16.88M sh · $285.54M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 4.53M sh · $76.60M · Q2 2026
- REGENERON PHARMACEUTICALS, INC. 3.70M sh · $62.65M · Q2 2026
- Amova Asset Management Americas, Inc. 2.90M sh · $49.03M · Q2 2026
- Contrarius Group Holdings Ltd 1.96M sh · $33.08M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.50M sh · $25.38M · Q2 2026
- Ghisallo Capital Management LLC 1.20M sh · $20.30M · Q2 2026
- IQ EQ FUND MANAGEMENT (IRELAND) Ltd 777.95K sh · $13.16M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held NTLA?
Opaleye Management Inc. has disclosed NTLA holdings in 5 of the last 11 reported quarters, going back to Q4 2023.
What is Opaleye Management Inc.'s current position in NTLA?
As of Q2 2026, Opaleye Management Inc. holds 250.00K shares of NTLA (INTELLIA THERAPEUTICS INC), valued at $4.23M, representing 0.38% of its reported portfolio and ranking #38.
Has Opaleye Management Inc. been buying or selling NTLA?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. increased its position in NTLA. The position peaked in Q1 2024 at 255.00K shares.
Which other funds hold NTLA?
Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., REGENERON PHARMACEUTICALS, INC., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.